<ul><li> Massachusetts-based AI drug discovery company METiS Therapeutics has raised USD 64 million in a Series A-2 funding round, bringing the total Series A funds to USD 150 million (the previous Series A round closed in December 2021 ). Both rounds were led by PICC Capital and China Life Private Equity Investment with participation from Sequoia Capital China, Lightspeed China Partners, and other investors.</ul>
The proceeds will be directed toward accelerating the company’s R&D efforts including the development of its AI drug discovery and delivery platform “AiTEM,” and advancing a few of its drug candidates into clinical trials in early 2022.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.